FindTrial
Sign In

AZA

DRUG6 trials

Sponsors

Merck Sharp & Dohme LLC, Qualitix Clinical Research Co., Ltd., Daiichi Sankyo, OncoVerity, Inc., Chinese SLE Treatment And Research Group

Conditions

Acute Myelogenous LeukemiaAcute Myeloid LeukemiaChronic Myelomonocytic LeukemiaCrohn's DiseaseLeukemia, Myeloid, AcuteMyasthenia GravisMyelodysplastic SyndromeMyelodysplastic Syndromes

Phase 1

Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
TerminatedNCT02319369
Daiichi SankyoAcute Myelogenous Leukemia, Myelodysplastic Syndrome
Start: 2014-11-25End: 2020-08-21Updated: 2021-10-11
A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)
CompletedNCT03030612
OncoVerity, Inc.Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Start: 2016-12-31End: 2022-08-31Updated: 2023-08-09
A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
CompletedNCT04609826
Janssen Research & Development, LLCAcute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes
Start: 2020-11-26End: 2025-08-25Updated: 2025-10-01

Phase 3

Efficacy of Infliximab in the Treatment of Patients Affected by Corticodependent Crohn's Disease (P02732)
TerminatedNCT00796250
Merck Sharp & Dohme LLCCrohn's Disease
Start: 2003-11-01End: 2005-01-01Updated: 2017-03-23
Comparison of Mycophenolate Mofetil and Cyclophosphamide for Active Takayasu's Arteritis
CompletedNCT03096275
Chinese SLE Treatment And Research GroupTakayasu Arteritis
Start: 2017-03-16End: 2022-11-11Updated: 2023-08-30

Unknown Phase

Trial of Mycophenolic Acid Versus Azathioprine in the Treatment of Corticosteroid-refractory Myasthenia Gravis
NCT00997412
Qualitix Clinical Research Co., Ltd.Myasthenia Gravis
Start: 2009-05-31End: 2011-05-31Target: 40Updated: 2009-10-19

Related Papers

Trial in Progress: A Multicenter, Open Label, Randomized, Phase 2 Study of Venetoclax and Azacitidine Plus Cusatuzumab Versus Venetoclax and Azacitidine Alone in Newly Diagnosed AML Patients Who Are Not Candidates for Intensive Therapy
Blood2024-11-05
Clonal Expansion of Mutant p53 Clones By MDM2 Inhibition in Acute Myeloid Leukemias
Blood2020-11-042 citations
Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents.
2020-06-29170 citations
CULMINATE: A phase II study of cusatuzumab + azacitidine in patients with newly diagnosed AML, ineligible for intensive chemotherapy.
Journal of Clinical Oncology2020-05-2010 citations
Targeting CD70 with Cusatuzumab Eliminates Acute Myeloid Leukemia Stem Cells in Humans
Blood2019-11-1311 citations
A Phase 1 Dose Escalation Study of Milademetan in Combination with 5-Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Blood2019-11-134 citations
Argx-110 Targeting CD70, in Combination with Azacitidine, Shows Favorable Safety Profile and Promising Anti-Leukemia Activity in Newly Diagnosed AML Patients in an Ongoing Phase 1/2 Clinical Trial
Blood2018-11-2920 citations
Phase 1 Dose Escalation Study of MDM2 Inhibitor DS-3032b in Patients with Hematological Malignancies - Preliminary Results
Blood2016-12-0237 citations